Responsive, knowledgeable and easy-to-work-with health care regulatory counsel

Susan Brichler Trujillo works with clients across the pharmaceutical drug and device distribution chain, helping manufacturers, distributors and health care providers operate successfully within their highly regulated industry. With clients including retail pharmacies, pharmacy wholesales, durable medical equipment (DME) providers, pharmaceutical distributors, pharmacy benefit managers, hospitals, behavioral health providers, residential care providers and licensed professionals, Susan advises on:

• Regulatory compliance, including licensure and permitting
• Administrative law matters

Maintaining open lines of communication and good relationships with regulators throughout the United States, and always cognizant of a client’s risk tolerance and business goals, Susan delivers solutions for her clients that minimize risk and make the most of market opportunities.

Susan is chair of the Phoenix office Health & Life Sciences Practice Group.

Bar Admissions

• Arizona

Education

• University of Arizona (M.A., 1998)

• University of Arizona (B.A., 1995)

• University of Notre Dame Law School (J.D., 2004)
  • Hon. Roslyn O. Silver, U.S. District Court, District of Arizona (Judicial Intern, 2001)

• "Alabama Battle Over Alprazolam is Done. For Now."
• "Alabama Continues Efforts to Make Alprazolam a Schedule II Drug"
• "DEA Finalizes Rule to Schedule Tramadol"
• "Industry/Business of Pharmacy"
• "Legislative Sweeps: An Update on Recent Cases"
• "New and Improved? - A Discussion of New and Proposed State Regulations"
• "Pharmacy Case Law Update"
• "Pharmacy Compliance and Case Law Review"
• "Pharmacy Law Practices Within Health Systems"
• "State Law Updates"
• "Wyeth v. Levine, 555 U.S.____, No. 06-1249, Warning! Excluding Known Hazards from FDA-Approval Labeling Contraindicated"
• 503B Loses Federal Preemption Argument, Appeals to Ninth Circuit
• California Board of Pharmacy Considers New Legislation Regarding Pharmacy Workplace Conditions
• Alabama Battle Over Alprazolam is Done. For Now.
• Alabama Closer to Making Alprazolam a Schedule II Drug
• Alabama Designates Gabapentin as a Schedule V Drug
• Applications Now Available for Alaska's New Licensing Categories and Prescription Standards
• Are You Interested in the FDA's Guidance on Outsourcing Facilities? Your Time to Comment Is Ending Soon!
• Board’s Economic Impact Analysis Disputes Industry Submissions, Board Advances Proposed Rule Without Changes
• Chicago Commissioner of Public Health Publishes Proposed Pharmaceutical Representative Licensing Rules
• FDA May Require Opioids to be Dispensed with Mail-Back Envelopes and Related Patient Education
• FDA Releases Flurry of Compounding-Related Documents
• FDA Releases Guidance on Identification of Suspect Product and Notification
• Federal Court Deals Blow to FDA’s Compounding MOU
• Health Care Providers Beware: Congress Expands The False Claims Act
• High Court Rules “State of Mind” Relevant in Prosecuting Prescribers under the Controlled Substance Act
• HIPAA Has Some New Teeth: Update on Interim Final Rule On "Improved Enforcement" Under HITECH
• Hot Off the Press: Mississippi Board of Pharmacy Files Proposed Rule on Shared Pharmacy Services
• New FDA Draft Compounding Guidance for Pharmacies, Hospitals, and Outsourcing Facilities
• New Wisconsin Patient Consultation Rule Affecting Resident and Non-Resident Pharmacies to Take Effect on January 1, 2021
• OIG Gives a Thumbs Down to Specialty Pharmacy Prescription Transfer Program
• Oklahoma Board of Pharmacy Proposes Temperature Control Rule for Shipping Drugs
• Oklahoma Will Require Nonresident Pharmacy to Have an Oklahoma-Licensed Pharmacist-in-Charge
• Puerto Rico Implements Licensure Requirement for Non-Resident Wholesalers & Manufacturers
• Results of Economic Impact Discussion: The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies
• Susan Brichler Trujillo and Eric Johnson Write InBusiness Phoenix Article About How COVID Continues to Affect Businesses
• The Clock is Ticking: Comments to Proposed Federal Rules For Wholesalers and 3PLs are Due June 6th and Here’s What We Think
• The FDA Announces Delays in DSCSA Compliance Requirements and Issues Final Version of Compounding Drug Memorandum of Understanding
• The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies
• The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Board Submits Final Rule Draft
• The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Potential Relief for Mail Order Pharmacies?
• Update on Status of Proposed Wisconsin Patient Counseling Rule that Will Impact Mail Order Pharmacies
• US District Court for District of Arizona Holds That Amount Accepted as Payment in Full is Reasonable Expenses Incurred for Necessary Medical Services
• Washington Eliminates Technician to Pharmacist Ratio
• Will Alabama Make Alprazolam a Schedule II Drug?

Seminar

• 2019 Pharmacy Law Symposium
• 2021 Pharmacy Law Symposium